https://www.pacificejournals.com/journal/index.php/apalm/issue/feed Annals of Pathology and Laboratory Medicine 2022-12-01T20:39:56+00:00 Dr. Prashant Goyal editor.apalm@pacificejournals.com Open Journal Systems <p><strong>Annals of Pathology and Laboratory Medicine (APALM)</strong> is an international, Double-blind peer-reviewed, indexed, open access, online and print journal&nbsp;for pathologists, microbiologist, biochemist and clinical laboratory scientists, and is published by <strong><a href="https://www.pacificejournals.com" target="_blank" rel="noopener"><strong>Pacific group of e-Journals</strong>' (<strong>PaGe</strong>)</a>, </strong>an&nbsp;<em>ISO 9001:2008</em> Certified&nbsp;academic publishing house.</p> <p>Set up in 2014, APALM is a specialized journal, which publishes original, peer-reviewed articles&nbsp;in the field of Pathology and Laboratory Medicine which, <em>inter alia</em>, includes Histopathology, Cytopathology, Hematology, Clinical Pathology, Forensic Pathology, Blood Banking, Clinical Bio-Chemistry, Medical Microbiology (Bacteriology, Virology, Mycology, Parasitology), etc.</p> <p><strong>DOI: 10.21276/APALM (<a title="Verify APALM DOI " href="https://dx.doi.org/10.21276/apalm" target="_blank" rel="noopener">https://dx.doi.org/10.21276/apalm</a>)<br></strong></p> <p>&nbsp;</p> https://www.pacificejournals.com/journal/index.php/apalm/article/view/3195 An Immunohistochemical Study for Mammalian Target of Rapamycin Signaling Pathway Including Interacting PTEN in Prostatic Acinar Adenocarcinoma and Correlation with the Patient Clinicopathological Parameters 2022-12-01T20:39:55+00:00 Somaia Ahmed Saad El-Din drsomaia2005@gmail.com Shaimaa Abdel Moety shaymaa@squ.edu.om Khalid Al Hashmi abumutaz02@yahoo.ca Shadia Al Sinawi Shadia_72@hotmail.com Suaad Al-Badi Albadi.s@squ.edu.om Afrah Al Rashdi Afra7@squ.edu.om Samya Al Husani samya.alhusaini@squ.edu.om Hajer Albadi Hajer1610@gmail.com Asem Shalaby asemali444@yahoo.com <p><strong>Background</strong>: The activation of AKT-mTOR-PTEN pathway may promote prostate cancer progression and affects response to targeted therapies. The full extent of this activation remains to be determined. Our aim: was to assess the expression of inactive mTOR, phosphor-mTOR, phosphor-AKT and loss of PTEN in prostatic adenocarcinomas then correlate their expression with the clinicopathological parameters.</p> <p><strong>Methods</strong>: The study included 166 prostatic adenocarcinoma tissues using immunohistochemistry on tissue microarrays. Statistical analysis considering markers expression and correlation with the clinicopathologic parameters was done using appropriate tests.</p> <p><strong>Result</strong>: The mean age was 72.63 and 75.9% were clinically high risk. Gleason score 7 and WHO grade group 5 were the commonest (31.3% and 31.9% respectively). Most patient (73.1%) were stage T2 or higher. Expression of inactive mTOR, phospho-mTOR and phosphor-AKT was seen in 96.1%, 93.5% and 95.9% respectively. The loss of PTEN expression was noted in 55.3%.&nbsp; There were significant correlations between Gleason pattern 4 and the expression of inactive mTOR (p value &lt;0.001 and 0.004 respectively) and phospho-mTOR (p value 0.003 and 0.001 respectively). Gleason score 7 was significantly correlated to inactive mTOR expression (p value &lt;0.001). There was also significant correlation between phosphor-AKT and phospho- mTOR expression with p value 0.004.</p> <p><strong>Conclusion</strong>: The immunohistochemical expression of inactive mTOR, phosphor-mTOR and phosphor-AKT and loss of PTEN was appreciated in most prostate cancer cases, suggesting that activation of this pathway occur early during prostate tumorigenesis. This may indicate that targeting mTOR pathway may have a promising therapeutic role in the management of prostatic adenocarcinoma.&nbsp; </p> 2022-12-01T20:34:35+00:00 ##submission.copyrightStatement## https://www.pacificejournals.com/journal/index.php/apalm/article/view/3200 Solid Papillary Carcinoma: A Clinicopathological Evaluation of a Rare Variant of Carcinoma Breast 2022-12-01T20:39:55+00:00 Dhruvi Neel Shah shahneel89@yahoo.com Yogesh Mistry yogesh.mistry@greenashram.org Bhawana Chaudhry bhawana.chaudhry@greenashramm.org Rakshit Shah rakshit.shah@greenashram.org <p><strong>Background</strong>: Solid papillary carcinoma (SPC) of the breast is considered a low grade carcinoma with a favorable prognosis. We aimed to describe clinicopathologic features including immunohistochemistry expression profile and to delineate adverse prognostic features, if any.</p> <p><strong>Methods:</strong> Patients diagnosed with SPC between the years 2016–2022 were retrospectively identified from the archives at Kailash Cancer Hospital and Research Centre, Goraj. Microscopic slides and clinical history were reviewed. Immunohistochemical stains were performed.</p> <p><strong>Results:</strong> Of 12 SPCs cases retrieved, 11 (92%) were associated with ductal carcinoma in situ (DCIS). The median tumour size was 1.6cm (range 1.3-7.0cm). All tumors were positive for hormone receptor expression and negative for HER-2Neu. 6 cases (50%) show neuroendocrine differentiation. Lymph node involvement was identified in 4/12 (33.3%) patients. Of 12 patients with outcome data (median follow-up 30 months, range 7-72 months), none (0%) developed local recurrence. No distant metastasis or deaths were observed.</p> <p><strong>Conclusions: </strong>SPCs has excellent prognosis with no local recurrence or distant metastasis in this study. Axillary node metastasis is found to be associated with larger tumor size, however it appears to have no impact on disease free or overall survival.</p> 2022-12-01T20:34:59+00:00 ##submission.copyrightStatement##